WHWK Stock Analysis: Buy, Sell, or Hold?
WHWK - Whitehawk Therapeutics, Inc. Common Stock
$4.37
-0.09 (-2.02%)
▼
5d:
+6.59%
30d:
+1.63%
90d:
+19.73%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When WHWK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: WHWK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: WHWK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: WHWK is currently trading at $4.37, which is considered fair relative to its 30-day fair value range of $4.10 to $4.58.
Technical Outlook: Technically, WHWK is in a strong uptrend. Immediate support is located at $3.96, while resistance sits at $5.00.
Market Sentiment: WHWK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $6.50 (+48.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, WHWK is in a strong uptrend. Immediate support is located at $3.96, while resistance sits at $5.00.
Market Sentiment: WHWK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $6.50 (+48.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.10 -
$4.58
Company Quality Score
53/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
68.8%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.7% below Wall St target ($6.50)
Trading Range Analysis
30-Day Trading Range
$4.10 -
$4.58
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.54
(35.3%)
Support & Resistance Levels
Support Level
$3.96
Resistance Level
$5.00
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.57
Wall Street Target
$6.50
(+48.7%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 23, 2026 11:23 PM ET
Data refreshes hourly during market hours. Next update: 12:23 AM
Data refreshes hourly during market hours. Next update: 12:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is WHWK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Scott M Giacobello
SELL
141600 shares
2026-04-16
Scott M Giacobello
SELL
77000 shares
2026-04-15
Bryan Ball
SELL
92460 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |